These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23958918)

  • 1. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.
    Kohlmann A; Nadarajah N; Alpermann T; Grossmann V; Schindela S; Dicker F; Roller A; Kern W; Haferlach C; Schnittger S; Haferlach T
    Leukemia; 2014 Jan; 28(1):129-37. PubMed ID: 23958918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
    Greif PA; Konstandin NP; Metzeler KH; Herold T; Pasalic Z; Ksienzyk B; Dufour A; Schneider F; Schneider S; Kakadia PM; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Haematologica; 2012 Dec; 97(12):1909-15. PubMed ID: 22689681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
    Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
    Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
    Metzeler KH; Bloomfield CD
    Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
    Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
    Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.
    Tang JL; Hou HA; Chen CY; Liu CY; Chou WC; Tseng MH; Huang CF; Lee FY; Liu MC; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Lin LI; Tien HF
    Blood; 2009 Dec; 114(26):5352-61. PubMed ID: 19808697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
    Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
    Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.
    Mangan JK; Speck NA
    Crit Rev Oncog; 2011; 16(1-2):77-91. PubMed ID: 22150309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing.
    Yu G; Yin C; Wu F; Jiang L; Zheng Z; Xu D; Zhou J; Jiang X; Liu Q; Meng F
    Oncol Rep; 2019 Dec; 42(6):2333-2344. PubMed ID: 31638252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine learning derived genomics driven prognostication for acute myeloid leukemia with
    Shaikh AF; Kakirde C; Dhamne C; Bhanshe P; Joshi S; Chaudhary S; Chatterjee G; Tembhare P; Prasad M; Roy Moulik N; Gokarn A; Bonda A; Nayak L; Punatkar S; Jain H; Bagal B; Shetty D; Sengar M; Narula G; Khattry N; Banavali S; Gujral S; P G S; Patkar N
    Leuk Lymphoma; 2020 Dec; 61(13):3154-3160. PubMed ID: 32757686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.
    Grossmann V; Kern W; Harbich S; Alpermann T; Jeromin S; Schnittger S; Haferlach C; Haferlach T; Kohlmann A
    Haematologica; 2011 Dec; 96(12):1874-7. PubMed ID: 21828118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloidleukemia].
    Yang Y; Li T; Geng Y; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Nov; 40(11):1601-1606. PubMed ID: 33243739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis.
    Jalili M; Yaghmaie M; Ahmadvand M; Alimoghaddam K; Mousavi SA; Vaezi M; Ghavamzadeh A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):325-329. PubMed ID: 29479958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.